Navigation Links
Corgenix and BG Medicine Announce Supply Agreement for BGM Galectin-3(TM)
Date:12/14/2009

DENVER, Dec. 14 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, and BG Medicine, Inc. (BGM), a Waltham, Massachusetts-based life sciences company, announced today a supply agreement whereby Corgenix will manufacture BGM Galectin-3 diagnostic products in enzyme-linked immunosorbent assay (ELISA) microtiter format exclusively for BG Medicine. BG Medicine is seeking regulatory clearance in the United States of the BGM Galectin-3 kit for clinical use in patients with heart failure.

Galectins are a family of proteins that play an important role in organ fibrosis, and galectin-3 has been shown to play an important role in the development and progression of heart failure in animal and human studies. Heart failure is a common, complex, and serious medical condition that affects approximately six (6) million people in the U.S. alone. Once diagnosed, the prognosis is poor, with approximately 50% surviving for more than five years.

"We are extremely pleased to extend our collaboration with BG Medicine to include the manufacturing of the BGM Galectin-3 kit," said Douglass Simpson, Corgenix President and Chief Executive Officer. "BG Medicine is bringing cutting edge technology and science to the cardiology market and we look forward to a long-term relationship."

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases, and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process. More information is available at www.corgenix.com.

About BG Medicine

BG Medicine is a life sciences company focused on the discovery, development, and commercialization of novel molecular diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs. BG Medicine discovers biomarkers and is developing its diagnostic product candidates using its proprietary, versatile, and scalable technology platform which integrates and automates the precise measurement, analysis, characterization and interpretation of proteins and metabolites collected from bodily fluids. For more information about BG Medicine, see www.bg-medicine.com.

Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect", or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

SOURCE Corgenix Medical Corporation


'/>"/>
SOURCE Corgenix Medical Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Corgenix AspirinWorks(R) Test Recognized in POLYCAP Study at ACC.09
2. Corgenix, Tulane Announce Award of NIH Grant Extending Hemorrhagic Fever Virus Product Development Program
3. Corgenix to Host Conference Call to Discuss Fiscal 2010 First Quarter Results
4. Corgenix Reports Financial Results for First Quarter of Fiscal 2010
5. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
6. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
7. Personalized Medicine - The Genomic Revolution in Cardiac Care
8. Vaccine Study in New England Journal of Medicine Wrong in Concluding Mercury Exposures are Harmless, States SafeMinds
9. U.S. Preventive Medicine Acquires Specialty Disease Management
10. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
11. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)...  Two Bayer U.S. Pharmaceutical leaders received top awards ... 28 th Woman of the Year ... longstanding mission of furthering the advancement and impact of ... Cindy Powell-Steffen , senior director of brand activation and ... Libby Howe , a regional business manager for New ...
(Date:5/15/2017)... Inc., a privately-held CNS pharmaceutical company based in ... disease (PD), has enrolled the first patient in the RASMET ... study involving patients with PD and taking place at 12 ... period. The first stage is open label and involves single ... Denver , Boca Raton ...
(Date:5/10/2017)... Inc. (Nasdaq: HOLX ) announced today the ... April 1, 2017 .   GAAP diluted earnings per ... prior year period as the sale of the blood ... diluted EPS of $0.50 increased 6.4%.  Revenue of $715.4 ... Excluding the effects of blood screening and the acquired ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... ... CareFusion NOX-T3 portable sleep monitor with its Somnoware Sleep Device Interface (SDI). Somnoware ... for diagnostic device operations. With this platform, initializing devices and importing studies are ...
(Date:5/26/2017)... Sparks, Nevada (PRWEB) , ... May 26, 2017 ... ... to produce the first ever copper, antimicrobial, mesh back 24/7 task chair specifically ... and conference applications. “We are thrilled to partner with Cupron® to provide ...
(Date:5/26/2017)... Texas (PRWEB) , ... May 26, 2017 , ... Yisrayl ... a new publication this week that is focusing on the Peace Agreements being discussed ... his Middle East sprint in a race to try to speed up peace talks ...
(Date:5/26/2017)... Francisco, CA (PRWEB) , ... May 26, 2017 , ... ... Francisco, is proud to announce a new, informational blog post on insurance options. If ... surgery, checking insurance plans may help save time and money. Visiting an in-network provider ...
(Date:5/26/2017)... ... 26, 2017 , ... Centennial-based BluSky Restoration Contractors announced that ... Annual Clays for Kids fundraiser, to be held Friday, Sept. 22, at Kiowa ... part of BluSky’s partnership with The Adoption Exchange, BluSky will also share sponsorship ...
Breaking Medicine News(10 mins):